Search

Displaying results 9861 - 9870 of 10000 in total
  1. Drug

    Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16714
    ApprovedInvestigational

    * serotype 10A individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197). … Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae

  2. Drug

    Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16717
    ApprovedInvestigational

    * serotype 15B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197). … Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae

  3. Drug

    Influenza A virus A/Victoria/1/2020 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB16719
    Approved

    Synonyms: Influenza A virus A/Victoria/1/2020 (H1N1) live (attenuated) antigenCategories: Live Attenuated Influenza A Virus Vaccine
  4. Drug

    Lirentelimab

    go.drugbank.com/drugs/DB16728
    Investigational

    Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).

  5. Drug

    Favezelimab

    go.drugbank.com/drugs/DB16729
    Investigational

    Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A

  6. Drug

    IMCY-0141

    go.drugbank.com/drugs/DB17019
    Investigational

    IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin

  7. Drug

    NSC-663284

    go.drugbank.com/drugs/DB17038
    Experimental

    NSC-663284 is a potent quinolinedione Cdc25 phosphatase inhibitor.[A253052]

  8. Drug

    PIK-75

    go.drugbank.com/drugs/DB17047
    Experimental

    PIK-75 is a preferential p110 alpha/gamma PI3K inhibitor.[A253097]

    Synonyms: Benzenesulfonic acid, 2-methyl-5-nitro-, 2-((6-bromoimidazo(1,2-a)pyridin-3-yl)methylene)-1-methylhydrazide
  9. Drug

    RS-39604

    go.drugbank.com/drugs/DB17050
    Experimental

    RS-39604 is a selective 5-HT4 receptor antagonist.[A253112]

  10. Drug

    SB-218078

    go.drugbank.com/drugs/DB17051
    Experimental

    SB-218078 is a specific inhibitor of CHK1.[A253117]